GT
AXSM icon

Glenmede Trust’s Axsome Therapeutics AXSM Stock Holding History

Glenmede Trust’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Sell
942
-5,774
-86% -$1.25M ﹤0.01% 1282
2026
Q1 		$1.14M Sell
6,716
-208
-3% -$35.9K 0.01% 703
2025
Q4 		$1.26M Buy
+6,924
New +$967K 0.01% 663
2025
Q1 		$887K Buy
7,607
+2,141
+39% +$244K ﹤0.01% 736
2024
Q4 		$462K Sell
5,466
-2,007
-27% -$185K ﹤0.01% 960
2024
Q3 		$672K Buy
7,473
+70
+0.9% +$6.11K ﹤0.01% 839
2024
Q2 		$596K Buy
7,403
+101
+1% +$7.48K ﹤0.01% 842
2024
Q1 		$583K Sell
7,302
-63
-0.9% -$5.29K ﹤0.01% 873
2023
Q4 		$586K Sell
7,365
-838
-10% -$56K ﹤0.01% 846
2023
Q3 		$573K Buy
8,203
+4,031
+97% +$301K ﹤0.01% 802
2023
Q2 		$257K Hold
4,172
– – ﹤0.01% 1022
2023
Q1 		$257K Sell
4,172
-2,390
-36% -$157K ﹤0.01% 1027
2022
Q4 		$506K Sell
6,562
-8,999
-58% -$538K ﹤0.01% 833
2022
Q3 		$694K Buy
15,561
+9,876
+174% +$493K ﹤0.01% 738
2022
Q2 		$217K Buy
+5,685
New +$180K ﹤0.01% 1083
2022
Q1 		– Sell
-5,535
Closed -$209K – 1325
2021
Q4 		$209K Buy
+5,535
New +$204K ﹤0.01% 1143
2021
Q3 		– Sell
-5,500
Closed -$371K – 1294
2021
Q2 		$371K Sell
5,500
-235
-4% -$14.1K ﹤0.01% 973
2021
Q1 		$324K Buy
5,735
+60
+1% +$4.22K ﹤0.01% 962
2020
Q4 		$462K Buy
5,675
+562
+11% +$42K ﹤0.01% 858
2020
Q3 		$364K Buy
5,113
+2,480
+94% +$193K ﹤0.01% 874
2020
Q2 		$216K Sell
2,633
-2,473
-48% -$190K ﹤0.01% 985
2020
Q1 		$527K Hold
5,106
– – ﹤0.01% 889
2019
Q4 		$527K Sell
5,106
-899
-15% -$36.3K ﹤0.01% 889
2019
Q3 		$121K Buy
6,005
+2,545
+74% +$65.4K ﹤0.01% 1338
2019
Q2 		$89K Buy
+3,460
New +$69.4K ﹤0.01% 1440

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Glenmede Trust's AXSM Position: Q2 2026 in Review

Glenmede Trust reduced its Axsome Therapeutics (AXSM) stake by 86% in Q2 2026, selling an estimated $1.25M and leaving 942 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #1282.

Glenmede Trust first reported a position in AXSM in Q2 2019 and has held it in 25 quarters since. The position peaked at $1.26M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Glenmede Trust held 942 shares of Axsome Therapeutics worth $231K as of Q2 2026.
  • Glenmede Trust sold 5,774 Axsome Therapeutics shares in Q2 2026, an estimated $1.25M.
  • Axsome Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1282 holding.
  • Glenmede Trust first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 25 quarters since.
  • Glenmede Trust's Axsome Therapeutics position peaked at $1.26M in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.